熱門資訊> 正文
Elicio Therapeutics获得1000万美元融资
2025-06-04 20:03
- Elicio Therapeutics (NASDAQ:ELTX) has entered a $10M senior secured promissory note with existing investor, GKCC.
- The proceeds from the Note Financing, together with Elicio’s current cash and equivalents, are expected to support Elicio’s operations into the first quarter of 2026, beyond the anticipated AMPLIFY-7P Phase 2 interim analysis expected in the third quarter of 2025.
- The Co. received gross proceeds of $10M in the Note Financing.
- The Note bears an interest rate of up to 12.5%, and matures on June 3, 2028, and includes a 24-month interest-only period, and interest accrued during the first 12 months is payable in a lump sum beginning on the thirteenth month after closing.
More on Elicio Therapeutics
- Elicio Therapeutics grants inducement award to new chief strategy and financial officer
- Seeking Alpha’s Quant Rating on Elicio Therapeutics
- Historical earnings data for Elicio Therapeutics
- Financial information for Elicio Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
